Evidence map›Paper›PMID 42525323›Full record

ArticleInternational journal of clinical pharmacy2026

Global burden and future trends of type 2 diabetes mellitus-associated chronic kidney disease: analysis of the Global Burden of Disease Study 2021.

Naitao Shen, Shanshan Jin, Zhongyu Yue, Zhujin Song, Miaolian Wu

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Naitao Shen *Department of Pharmacy, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, Zhejiang, China.
Shanshan Jin *Department of Pharmacy, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, Zhejiang, China.
Zhongyu YueDepartment of Pharmacy, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, Zhejiang, China.
Zhujin SongDepartment of Pharmacy, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, Zhejiang, China.
Miaolian WuDepartment of Pharmacy, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, Zhejiang, China. chawml@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionType 2 diabetes mellitus-associated chronic kidney disease (T2DM-associated CKD) is a major cause of kidney failure, cardiovascular complications, and premature mortality. Understanding the global burden, major modifiable risk factors, and future trends of T2DM-associated CKD is essential for healthcare planning and management.

aimThis study aimed to characterize the global, regional, and national burden of T2DM-associated CKD from 1990 to 2021, evaluate the distribution of burden attributable to major modifiable risk factors, and project future disease burden through 2040 using data from the Global Burden of Disease (GBD) 2021 study.

methodData were obtained from the GBD 2021 study. The incidence, prevalence, mortality, and disability-adjusted life years (DALYs) for chronic kidney disease due to type 2 diabetes mellitus were analyzed. Decomposition analysis quantified the contributions of population growth, aging, and epidemiological changes. Risk factor analyses identified the leading modifiable contributors to mortality and disability-adjusted life years (DALYs). Future trends through 2040 were projected using an age-period-cohort model implemented with the NORDPRED package.

resultsFrom 1990 to 2021, the global burden of T2DM-associated CKD has increased substantially. The male age-standardized incidence rate increased from 19.07 (17.28-20.83) to 23.07 (21.40-24.72) per 100,000 population, and the age-standardized DALY rates also increased. High-SDI regions consistently had the highest incidence, whereas low- and low-middle-SDI regions experienced disproportionately high mortality and disability burdens. East Asia and South Asia contributed the largest number of incident cases, deaths, and DALYs. The disease burden increases markedly with age. Population growth (49.61%) and aging (30.53%) were the principal drivers of the increasing incidence. High fasting plasma glucose and elevated body mass index are the leading modifiable risk factors worldwide. The incidence is projected to continue increasing through 2040, whereas mortality and DALY rates are expected to stabilize or decline.

conclusionT2DM-associated CKD remains a substantial global health challenge, with marked geographic and socioeconomic disparities. These findings support the earlier identification of high-risk individuals, broader implementation of evidence-based renoprotective therapies, and strengthened long-term disease management, and may inform future healthcare planning, resource allocation, and strategies for preventing and managing T2DM-associated CKD.

Indexed as

Chronic kidney diseaseDiabetic kidney diseaseDisease burdenEpidemiologyRisk factorsType 2 diabetes mellitus

Identifiers

PMID42525323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.